The primary objective is to safely determine if the investigators can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled the investigators will draw blood and urine for novel and standard biomarkers. The investigators are attempting to determine if these biomarkers can forecast the course of AKI (need for dialysis, death and renal recovery). The investigators seek to determine how well physicians caring for those with AKI can predict the clinical course compared to these novel biomarkers of AKI and if there is an association between clinical course and 3 year patient outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Progression to Stage 3 AKI
Timeframe: within 7 days of furosemide administration
Receipt of Renal Replacement Therapy (RRT)
Timeframe: within 7 days of furosemide administration
Death
Timeframe: During the index hospital stay, an average of 17 days, until hospital discharge, or until death, whatever occurs first